- Home
- CSTL vs NBBK Comparison
CSTL vs NBBK Comparison
Compare CSTL & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- NBBK
- Stock Information
- Founded
- CSTL 2007
- NBBK 1892
- Country
- CSTL United States
- NBBK United States
- Employees
- CSTL N/A
- NBBK N/A
- Industry
- CSTL Medical Specialities
- NBBK
- Sector
- CSTL Health Care
- NBBK
- Exchange
- CSTL Nasdaq
- NBBK Nasdaq
- Market Cap
- CSTL 661.7M
- NBBK 718.5M
- IPO Year
- CSTL 2019
- NBBK N/A
- Fundamental
- Price
- CSTL $33.02
- NBBK $18.50
- Analyst Decision
- CSTL Strong Buy
- NBBK Buy
- Analyst Count
- CSTL 6
- NBBK 1
- Target Price
- CSTL $38.67
- NBBK $22.00
- AVG Volume (30 Days)
- CSTL 421.5K
- NBBK 237.7K
- Earning Date
- CSTL 11-03-2025
- NBBK 10-22-2025
- Dividend Yield
- CSTL N/A
- NBBK 1.51%
- EPS Growth
- CSTL N/A
- NBBK 423.26
- EPS
- CSTL N/A
- NBBK 1.55
- Revenue
- CSTL $343,530,000.00
- NBBK $189,481,000.00
- Revenue This Year
- CSTL N/A
- NBBK N/A
- Revenue Next Year
- CSTL N/A
- NBBK N/A
- P/E Ratio
- CSTL N/A
- NBBK $11.96
- Revenue Growth
- CSTL 10.15
- NBBK 30.69
- 52 Week Low
- CSTL $14.59
- NBBK $15.09
- 52 Week High
- CSTL $34.64
- NBBK $21.05
- Technical
- Relative Strength Index (RSI)
- CSTL 81.56
- NBBK 58.62
- Support Level
- CSTL $23.31
- NBBK $17.16
- Resistance Level
- CSTL $34.36
- NBBK $18.28
- Average True Range (ATR)
- CSTL 1.50
- NBBK 0.52
- MACD
- CSTL 1.08
- NBBK 0.07
- Stochastic Oscillator
- CSTL 89.19
- NBBK 76.14
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.